SPPI Stock Overview
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products.
Spectrum Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.48|
|52 Week High||US$2.45|
|52 Week Low||US$0.41|
|1 Month Change||-58.10%|
|3 Month Change||-38.76%|
|1 Year Change||-78.58%|
|3 Year Change||-93.88%|
|5 Year Change||-96.75%|
|Change since IPO||-99.65%|
Recent News & Updates
Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|SPPI||US Biotechs||US Market|
Return vs Industry: SPPI underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: SPPI underperformed the US Market which returned -22.1% over the past year.
|SPPI Average Weekly Movement||18.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SPPI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: SPPI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company’s products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002.
Spectrum Pharmaceuticals Fundamentals Summary
|SPPI fundamental statistics|
Is SPPI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SPPI income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.64|
|Net Profit Margin||0.00%|
How did SPPI perform over the long term?See historical performance and comparison
Is SPPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPPI?
Other financial metrics that can be useful for relative valuation.
|What is SPPI's n/a Ratio?|
Price to Book Ratio vs Peers
How does SPPI's PB Ratio compare to its peers?
|SPPI PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CLGN CollPlant Biotechnologies
TSHA Taysha Gene Therapies
SPPI Spectrum Pharmaceuticals
Price-To-Book vs Peers: SPPI is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (1.8x).
Price to Earnings Ratio vs Industry
How does SPPI's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: SPPI is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is SPPI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate SPPI's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of SPPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SPPI ($1.06) is trading below our estimate of fair value ($26.23)
Significantly Below Fair Value: SPPI is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Spectrum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPPI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: SPPI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SPPI is expected to become profitable in the next 3 years.
Revenue vs Market: SPPI's revenue (59.5% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: SPPI's revenue (59.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPPI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Spectrum Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPPI is currently unprofitable.
Growing Profit Margin: SPPI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPPI is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare SPPI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPPI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: SPPI has a negative Return on Equity (-350.67%), as it is currently unprofitable.
Discover strong past performing companies
How is Spectrum Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SPPI's short term assets ($73.6M) exceed its short term liabilities ($41.0M).
Long Term Liabilities: SPPI's short term assets ($73.6M) exceed its long term liabilities ($4.9M).
Debt to Equity History and Analysis
Debt Level: SPPI is debt free.
Reducing Debt: SPPI has no debt compared to 5 years ago when its debt to equity ratio was 50.1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPPI has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SPPI is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
What is Spectrum Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Spectrum Pharmaceuticals Dividend Yield vs Market|
|Company (Spectrum Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Spectrum Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate SPPI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPPI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPPI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPPI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SPPI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Riga (47 yo)
Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...
CEO Compensation Analysis
|Tom Riga's Compensation vs Spectrum Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$3m||US$550k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$3m||US$550k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$4m||US$550k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$5m||US$500k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$1m||US$420k|
Compensation vs Market: Tom's total compensation ($USD2.79M) is above average for companies of similar size in the US market ($USD784.47K).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
Experienced Management: SPPI's management team is considered experienced (2.3 years average tenure).
Experienced Board: SPPI's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|03 Jan 22||BuyUS$20,000,000||Hanmi Pharm. Co., Ltd.||Company||12,500,000||US$1.60|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Spectrum Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Spectrum Pharmaceuticals, Inc.
- Ticker: SPPI
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$87.767m
- Shares outstanding: 183.73m
- Website: https://www.sppirx.com
Number of Employees
- Spectrum Pharmaceuticals, Inc.
- Pilot House – Lewis Wharf
- 6th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SPPI||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Sep 1996|
|NTR||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Sep 1996|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.